NGRC Share Price Performance
US$0.043
-0.02 (-28.07%)
Price US$0.043
Share PriceUS$0.043
NGRC Community Narratives
There are no narratives available yet.
Recent NGRC News & Updates
No updates
National Graphite Corp. Key Details
Last Reported Earnings
May 31, 2015
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- 0
- Gross Margin
- 0%
- Net Profit Margin
- 0%
- Debt/Equity Ratio
- 0%
National Graphite Corp. Competitors
About NGRC
- Founded
- 2006
- Employees
- n/a
- CEO
- Website
National Graphite Corp., through its subsidiary, Biotech Development Corp., operates as a biopharmaceutical risk/cost-sharing company. The company collaborates with clinical stage companies that develop new biological entities or new therapeutically platforms for the treatment of various diseases, rare diseases, and diseases with unmet needs. It is developing a drug candidate called ELAFIN, which is a human identic protein for the treatment of postoperative inflammatory complications. National Graphite Corp. has a collaboration agreement with Proteo Inc. for developing ELAFIN. The company was formerly known as Lucky Boy Silver Corporation and changed its name to National Graphite Corp. in May 2012. National Graphite Corp. was founded in 2006 and is based in Duesseldorf, Germany.
German Market Performance
- 7 Days: -1.2%
- 3 Months: -3.2%
- 1 Year: 22.4%
- Year to Date: 6.1%
The market has climbed 1.2% in the last 7 days, lead by the Communication Services sector with a gain of 13%. On the other hand, with a decline of 4.7%, the Consumer Discretionary sector is lagging behind. The market is up 24% over the last 12 months. Earnings are forecast to grow by 17% annually. Market details ›
This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
Continue reading